Key facts
- Neuromagen Pharma’s last known valuation is $13.6M (Dec 2024).
- It has raised $8.5M; the latest was Early Stage VC ($5.0M) in Sep 2025.
- Notable investors include Innovation Authority.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Neuromagen Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Neuromagen Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neuromagen Pharma
Developer of novel anti-aging drugs designed for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis. The company's drug enhances the effectiveness of telomerase as a neuroprotectant, delaying the onset and progression of amyotrophic lateral sclerosis, enabling physicians to treat neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Beer Sheva, Israel
- Founded
- 2021
- Employees
- 4
- Website
- neuromagen.com/
- Ownership
- Privately Held (backing)
Neuromagen Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuromagen Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuromagen Pharma in its N-PORT filings yet. We sweep new filings monthly.